Indication and Important Safety Information | Full Prescribing Information
Who should take Somatuline® Depot
(lanreotide) Injection?

Somatuline Depot is indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to other types of treatment, like:

  • Surgery
  • Radiation
  • Other medications

Somatuline® Depot (lanreotide) Injection is also for patients who cannot tolerate surgery because they do not react well to general anesthesia, or to radiation treatments, which can be very fatiguing.

The goal of treatment with Somatuline® Depot (lanreotide) Injection, and all treatments for acromegaly, is to have normal levels of growth hormone and growth factors in the blood.

Could Somatuline® Depot (lanreotide) Injection help you?

Read about three patients with acromegaly who are well suited to take Somatuline® Depot (lanreotide) Injection. See if you're like Dave, or Mark, or Karen.

How does Somatuline® Depot (lanreotide) Injection?

By mimicking a natural hormone, it helps your body control acromegaly. Learn more about how Somatuline Depot works.

How to take Somatuline® Depot (lanreotide) Injection

Somatuline® Depot (lanreotide) Injection is injected in a simple, easy injection process. Learn more about how easy it is to inject Somatuline® Depot (lanreotide) Injection.

Indication and Important Safety Information

Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline Depot may experience hypoglycemia or hyperglycemia. Glucose level monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline Depot 60 mg.

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus.

A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline Depot may reduce the intestinal absorption of coadministered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), injection-site reaction (9%), flatulence (7%), arthralgia (7%), and loose stools (6%).

For Full Prescribing Information, click here.